Module 5 Readings

Required:

Metarrestin research in Science Translational Medicine (We've been referring to this throughout, but you may want to review the animal data Dr. Rudloff presented)

Frankowski KJ, Wang C, Patnaik S, et al. (2018). Metarrestin, a perinucleolar compartment inhibitor, effectively suppresses metastasis. *Science Translational Medicine*, 16;10(441).

In Vitro vs. In Vivo Research Findings (mentioned in Dr. Rudloff's presentation)

Johnson JI, Decker S, Zaharevitz D, Rubinstein LV, Venditti JM, Schepartz S, Kalyandrug S, Christian M, Arbuck S, Hollingshead M, Suasville EA. (2001). Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials. *British Journal of Cancer*. 18;84(10)1424-31.

Metarrestin metabolism and pharmacokinetic study

Padilha E, Wang A, Singleton M, Hughes E, Li D, Rice K, Konrath K, Patnaik, S, Marugan J, Rudloff U, and Xu, X. (2020). Metabolism and pharmacokinetic characterization of Metarrestin in multiple species. Cancer Chemotherapy and Pharmacology.

Recommended:

Press related to the release of the Frankowski et al, 2018 paper

National Cancer Institute. (2018). Experimental Cancer Drug Metarrestin Targets Metastatic Tumors.

National Center for Advancing Translational Sciences. (2018). Metarrestin for the Treatment of Pancreatic Cancer.

National Institutes of Health. (2018). NIH, Northwestern scientists develop potential new approach to stop cancer metastasis.

Northwestern University: Paul, M. (2018). A "dirty bomb" battles cancer metastasis.

University of Kansas Cancer Center. (2018). Researchers identify metastasis-suppressing compound.